person · Reporting owner
Kavanaugh William Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | CSO, Head Res.&Non-Clin. Dev. | February 14, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2030-02-13 | Direct | 120,000 |
Reported balance
After 2020-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 120,000 · Balance 120,000 F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 19, 2020 23:41 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-20-004348 · doc1.xml · derivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 00:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001567619-19-001866 · doc1.xml · derivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $25.82 | $0.00 |
DisclosureSEC source: 0001140361-18-003375 · doc1.xml · derivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 19:35 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,130 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001140361-17-045842 · doc1.xml · derivative · entry 2 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,912 Underlying: Common Stock · 5,130 shares Expires 2025-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on January 9, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 19:35 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 5,130 | $1.57 | $8,079.24 |
DisclosureSEC source: 0001140361-17-045842 · doc1.xml · nonDerivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,368 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-17-037761 · doc1.xml · derivative · entry 3 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,368 Underlying: Common Stock · 48,368 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 48,368 | $24.34 | $1,177,277.12 |
DisclosureSEC source: 0001140361-17-037761 · doc1.xml · nonDerivative · entry 2 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,917 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stok | 48,368 | $4.47 | $216,340.39 |
DisclosureSEC source: 0001140361-17-037761 · doc1.xml · nonDerivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2017 Filed Apr 17, 2017 22:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 48,368 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-17-016029 · doc1.xml · derivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,736 Underlying: Common Stock · 48,368 shares Expires 2025-05-06 F1 · derivative.exercise_date: On May 7, 2015, the Reporting Person was granted an option to purchase 96,736 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On September 26, 2016, the first performance milestone was achieved resulting in 50% of the Performance Option vesting. On April 14, 2017, the second performance milestone was achieved resulting in the remaining 50% of the Performance Option vesting. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:53 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001140361-17-003158 · doc1.xml · derivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 23:12 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 48,368 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-16-080947 · doc1.xml · derivative · entry 1 Kavanaugh William Michael · CIK 0001578767 · CSO, Head Res.&Non-Clin. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,368 Underlying: Common Stock · 48,368 shares Expires 2025-05-06 F1 · derivative.exercise_date: On May 7, 2015, the Reporting Person was granted an option to purchase 96,736 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On September 26, 2016, the first performance milestone was achieved resulting in 50% of the Performance Option vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.